YOLFTbeta
Green Cross Medical Science Corporation

Green Cross Medical Science Corporation

142280 · KQ · Healthcare / Drug Manufacturers - Specialty & Generic

2,885.00KRW-10.00 (-0.35%)

Price History

Full chart

Market Stats

Previous Close2,895.00
Open2,895.00
Day Range2,850.00 – 2,975.00
52-Week Range2,200.00 – 6,660.00
Volume183.90K
Market Cap71.86B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.73
50-Day Avg2,942.40
200-Day Avg3,559.15

About

GC Medical Science Corporation operates as a diagnostic medical device company in the vitro diagnostic industry in South Korea and internationally. The company's products include human healthcare products for the diagnosis of diabetes, non-communicable diseases, respiratory diseases, and vector borne diseases. It offers CERA-CHEK 1Code and CERA-CHEK 1070 for diabetes; GREENCARE A1c for HbA1c, CERA-CHEK 3 in 1 GHL for multi-diagnosis; CERA-CHEK Lactate; GREENCARE Hb and CERA-CHEK Hb Plus for haemoglobin; and GCare Lipid and GCare Lipid Printer for cholesterol. The company also offers Covid-19 and flu diagnosis equipment including GENEDIA W Covid-19 Ag, GreenCare FLU2 Influenza A&B Ag, and " GENEDIA W Covid-19 & Flu A&B Ag. Additionally, it offers dengue diagnosis equipment including GENEDIA W Dengue NS1 Ag, GENEDIA W Dengue lgM/lgG Ab, and GENEDIA W Dengue NS1 & lgM/lgG Combo. Further, the company provides vet healthcare products, such as CERA-PET blood glucose monitoring system for diabetes; and CERA-PET Multi for non-communicable diseases diagnosis. The company was formerly known as Green Cross Medical Science Corporation and changed its name to GC Medical Science Corporation in May 2026. GC Medical Science Corporation was founded in 1972 and is headquartered in Yongin-Si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOSagong Younghee
  • Employees117
  • HeadquartersGCMS, Yongin-Si, South Korea, 446-770, Korea
  • Websitehttps://www.greencrossms.com

Leadership

  • Sagong YoungheePresident

Financials

Income Statement

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue81.33B89.30B86.16B98.39B86.32B94.09B113.38B101.67B113.11B94.01B103.85B108.41B
Growth (%)-+9.79%-3.51%+14.19%-12.26%+8.99%+20.50%-10.32%+11.25%-16.88%+10.47%+4.39%
Cost of Revenue66.41B75.92B73.70B82.98B78.14B84.62B93.56B100.00B100.30B79.99B89.00B93.26B
Gross Profit14.92B13.38B12.47B15.40B8.18B9.47B19.82B1.67B12.81B14.02B14.85B15.15B
Gross Margin18.35%14.98%14.47%15.66%9.48%10.07%17.48%1.65%11.32%14.92%14.30%13.98%
Operating Expense10.47B12.31B14.59B16.14B17.20B19.01B15.62B21.84B14.07B12.22B13.26B12.27B
Operating Income4.45B1.07B-2.12B-731.74M-9.01B-9.54B4.20B-20.16B-1.26B1.80B1.60B2.89B
Operating Margin5.47%1.20%-2.47%-0.74%-10.44%-10.14%3.70%-19.83%-1.12%1.92%1.54%2.66%
EBITDA--------4.03B9.03B10.01B8.73B
EBITDA Margin--------3.56%9.60%9.64%8.05%
Net Income3.72B729.32M-1.89B-1.35B-10.71B-16.20B6.72B-21.20B-3.58B1.80B3.58B3.67B
Net Income Margin4.57%0.82%-2.19%-1.37%-12.41%-17.22%5.92%-20.85%-3.17%1.91%3.45%3.38%
R&D1.02B1.15B1.65B1.82B2.06B2.19B2.65B2.13B2.17B2.88B3.38B3.11B
R&D as % of Total Revenue1.25%1.28%1.92%1.85%2.38%2.33%2.34%2.10%1.92%3.06%3.26%2.87%
Interest Expense000000466.80M1.17B2.88B3.31B2.82B2.74B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%0.41%1.15%2.54%3.52%2.72%2.53%

Balance Sheet

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets52.10B72.61B63.61B60.54B63.97B88.87B105.60B95.63B96.47B90.53B87.97B90.51B
Total Liabilities20.60B43.74B36.76B37.31B48.63B39.29B49.14B59.51B63.22B53.61B46.76B44.14B
Total Equity31.50B28.87B26.85B23.23B15.34B49.58B56.47B36.11B33.25B34.50B41.21B44.36B
Cash335.74M1.09B1.58B3.34B3.85B8.68B4.49B1.95M2.46M5.74B678.49M372.63M
Total Debt---9.80B24.55B8.59B15.76B-----
Net Debt------5.48B27.85B6.41B9.96B9.54B10.21B

Cash Flow

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-2.22B-5.45B10.25B3.11B-516.61M-4.11B-8.76B-18.20B10.88B4.24B3.66B7.20B
Investing Cash Flow-3.53B-7.08B-2.89B-501.72M-9.90B-22.18B2.61B-3.28B-5.67B-3.82B-3.26B-
Financing Cash Flow4.26B13.28B-6.89B-784.73M10.93B31.13B1.99B18.82B1.77B-3.43B-5.46B-
Capital Expenditure2.56B3.27B1.89B1.11B5.10B22.46B2.55B3.60B3.43B5.63B3.22B4.90B
Free Cash Flow-------11.34B-21.79B7.38B-1.64B384.06M2.30B
Dividends Paid478.00M478.00M----------
FCF to OCF------129.49%119.78%67.81%-38.68%10.49%31.91%

Earnings

Report DateMar 31, 2015Jun 30, 2015Sep 30, 2015Dec 31, 2015Mar 31, 2016Jun 30, 2016Sep 30, 2016Jan 23, 2017Apr 26, 2017Jul 25, 2017Oct 31, 2017Jan 22, 2018Apr 27, 2018Jul 31, 2018Oct 30, 2018Feb 12, 2019Apr 30, 2019Jul 30, 2019Oct 30, 2019Feb 10, 2020Apr 27, 2020Jul 28, 2020Nov 1, 2020Feb 8, 2021Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate----------------------------------------------
EPS Actual79.3284.1346.90-147.6214.76-23.89-75.53-77.98100.1833.27-2.49-310.00-136.15-181.96-323.26-284.67-103.59-933.91-114.23-265.3326.00138.0022.00132.2868.4148.70-140.93-982.58-120.96-24.39181.03-205.5993.86-13.0155.10-50.633.41-9.066.2516.98-30.51119.6862.5716.992.41-177.30
Surprise----------------------------------------------
Timing-------After-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hours-Pre-marketPre-marketAfter-hoursAfter-hoursAfter-hours-----------------------

Key Statistics & Ratios

Market Cap71.86B
Enterprise Value90.57B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.70
Price / Book1.40
Revenue (TTM)102.16B
Gross Profit (TTM)13.53B
EBITDA6.36B
Profit Margin-2.12%
Operating Margin2.74%
Return on Equity-4.00%
Return on Assets1.47%
Shares Outstanding21.74M
Shares Float11.93M
Beta0.73
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20151×
41.11Dec 29, 2015
20141×
41.11Dec 29, 2014

Stock Splits

  • Sep 30, 20192683:2206